Search
for
Sort by
Research 61–90 of 775
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Janus kinase inhibitors for alopecia areata: A narrative review
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Role of janus kinase inhibitors in the treatment of alopecia areata
- New drugs under investigation for the treatment of alopecias
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- The role of janus kinases in the treatment of autoimmune skin diseases
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Current and future pharmacotherapy for alopecia areata
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Application of Baricitinib in Dermatology
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis